BR112012024691A2 - composto, e, composição farmacêutica - Google Patents

composto, e, composição farmacêutica

Info

Publication number
BR112012024691A2
BR112012024691A2 BR112012024691A BR112012024691A BR112012024691A2 BR 112012024691 A2 BR112012024691 A2 BR 112012024691A2 BR 112012024691 A BR112012024691 A BR 112012024691A BR 112012024691 A BR112012024691 A BR 112012024691A BR 112012024691 A2 BR112012024691 A2 BR 112012024691A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
compounds
prophylaxis
formula
Prior art date
Application number
BR112012024691A
Other languages
English (en)
Other versions
BR112012024691B1 (pt
Inventor
Cote Bernard
Sing Li Chun
Gauvreau Danny
Burch Jason
St-Onge Miguel
Nguyen Natalie
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012024691(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of BR112012024691A2 publication Critical patent/BR112012024691A2/pt
Publication of BR112012024691B1 publication Critical patent/BR112012024691B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

composto, e, composição farmacêutica. os compostos heteroaromáticos da fórmula i: (i) são inibidores da transcriptase reversa do hiv, em que r^1^, r^2^, r^3^, r^4^ e r^5^ são aqui definidos. os compostos da fórmula i e seus sais farmaceuticamente aceitáveis são úteis na inibição da transcriptase reversa do hiv, na profilaxia e tratamento da infecção pelo hiv e na profilaxia, retardo do início ou progressão e tratamento da aids. os compostos e seus sais podem ser utilizados como ingredientes em composições farmacêuticas, opcionalmente em combinação com os outros antivirais, imunomoduladores, antibióticos ou vacinas.
BR112012024691-7A 2010-03-30 2011-03-28 compostos inibidores não nucleosídeos da transcriptase revesa ou sais farmaceuticamente aceitáveis dos mesmos e composição farmacêutica que os compreende BR112012024691B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US61/318,824 2010-03-30
US32157310P 2010-04-07 2010-04-07
US61/321,573 2010-04-07
PCT/CA2011/000320 WO2011120133A1 (en) 2010-03-30 2011-03-28 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
BR112012024691A2 true BR112012024691A2 (pt) 2019-07-02
BR112012024691B1 BR112012024691B1 (pt) 2020-11-17

Family

ID=44710363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024691-7A BR112012024691B1 (pt) 2010-03-30 2011-03-28 compostos inibidores não nucleosídeos da transcriptase revesa ou sais farmaceuticamente aceitáveis dos mesmos e composição farmacêutica que os compreende

Country Status (44)

Country Link
US (2) US8486975B2 (pt)
EP (2) EP2924034B1 (pt)
JP (2) JP5281718B2 (pt)
KR (1) KR101421861B1 (pt)
CN (1) CN102971308B (pt)
AR (1) AR080859A1 (pt)
AU (1) AU2011235568B2 (pt)
BR (1) BR112012024691B1 (pt)
CA (1) CA2794377C (pt)
CL (1) CL2012002744A1 (pt)
CO (1) CO6630126A2 (pt)
CR (1) CR20120503A (pt)
CY (3) CY1118774T1 (pt)
DK (2) DK2924034T3 (pt)
DO (1) DOP2012000256A (pt)
EA (1) EA024804B1 (pt)
EC (1) ECSP12012201A (pt)
ES (2) ES2536295T3 (pt)
FI (1) FIC20190021I1 (pt)
GE (1) GEP20156368B (pt)
HK (2) HK1175471A1 (pt)
HN (1) HN2012002039A (pt)
HR (2) HRP20150427T1 (pt)
HU (4) HUE031785T2 (pt)
IL (2) IL222030A (pt)
LT (3) LT2924034T (pt)
LU (2) LUC00113I2 (pt)
MA (1) MA34170B1 (pt)
ME (2) ME02570B (pt)
MX (1) MX2012011379A (pt)
MY (1) MY163979A (pt)
NI (1) NI201200146A (pt)
NL (1) NL300980I2 (pt)
NO (2) NO2019019I1 (pt)
NZ (1) NZ602670A (pt)
PE (1) PE20130158A1 (pt)
PL (2) PL2552902T3 (pt)
PT (2) PT2924034T (pt)
RS (2) RS55505B1 (pt)
SG (1) SG184347A1 (pt)
SI (2) SI2924034T1 (pt)
TN (1) TN2012000455A1 (pt)
TW (1) TWI458719B (pt)
WO (1) WO2011120133A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024804B1 (ru) * 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
BR112015005997A8 (pt) * 2012-09-26 2023-04-11 Merck Sharp & Dohme Composto
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9663490B2 (en) * 2012-12-05 2017-05-30 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
JP6387094B2 (ja) * 2013-11-22 2018-09-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 非ヌクレオシド逆転写酵素阻害剤の組成物
MX367369B (es) 2013-12-04 2019-08-16 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
WO2015153304A1 (en) * 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
US10603282B2 (en) 2015-12-02 2020-03-31 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
AU2018255954B2 (en) 2017-04-18 2024-04-04 Cipla Limited Combination therapy for use in treating retroviral infections
EP3749330A4 (en) 2018-02-06 2021-11-17 The General Hospital Corporation REPEAT RNA AS A BIOMARKER OF TUMOR IMMUNE REACTION
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
JP4485520B2 (ja) 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2005102989A1 (en) 2004-04-23 2005-11-03 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP1940782B1 (en) 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CA2705834A1 (en) * 2007-11-20 2009-05-28 Merck Sharp & Dohme Corp. Pyridinone non-nucleoside reverse transcriptase inhibitors
EA024804B1 (ru) * 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение

Also Published As

Publication number Publication date
PT2552902E (pt) 2015-06-02
PL2924034T3 (pl) 2017-07-31
NL300980I2 (nl) 2021-06-17
SG184347A1 (en) 2012-11-29
EA024804B1 (ru) 2016-10-31
EP2552902B1 (en) 2015-03-11
EP2924034A1 (en) 2015-09-30
CA2794377A1 (en) 2011-10-06
TW201139409A (en) 2011-11-16
US20130296382A1 (en) 2013-11-07
IL233334A (en) 2015-09-24
TWI458719B (zh) 2014-11-01
MA34170B1 (fr) 2013-04-03
ES2536295T3 (es) 2015-05-22
PE20130158A1 (es) 2013-02-28
HUS1900022I1 (hu) 2019-05-28
LTPA2019507I1 (lt) 2019-04-25
HK1175471A1 (en) 2013-07-05
ES2609636T3 (es) 2017-04-21
US8486975B2 (en) 2013-07-16
DK2552902T3 (en) 2015-06-15
ME02181B (me) 2015-10-20
SI2552902T1 (sl) 2015-10-30
NL300980I1 (nl) 2019-04-24
KR101421861B1 (ko) 2014-07-22
GEP20156368B (en) 2015-09-25
NI201200146A (es) 2013-03-18
NO2019019I1 (no) 2019-04-24
CY1118774T1 (el) 2017-07-12
KR20120128703A (ko) 2012-11-27
SI2924034T1 (sl) 2017-05-31
MY163979A (en) 2017-11-15
RS55505B1 (sr) 2017-05-31
EP2552902A4 (en) 2013-09-04
HRP20161680T1 (hr) 2017-01-27
CY2019025I1 (el) 2019-11-27
JP2013510800A (ja) 2013-03-28
EP2924034B1 (en) 2016-11-02
JP2013209405A (ja) 2013-10-10
JP5886790B2 (ja) 2016-03-16
LTC2552902I2 (lt) 2019-12-10
AR080859A1 (es) 2012-05-16
HUE031785T2 (en) 2017-08-28
IL222030A (en) 2014-07-31
EP2552902A1 (en) 2013-02-06
PT2924034T (pt) 2017-01-06
ECSP12012201A (es) 2012-10-30
FIC20190021I1 (fi) 2019-04-17
IL233334A0 (en) 2014-09-01
NO2019018I1 (no) 2019-04-24
CY2019025I2 (el) 2019-11-27
LTC2924034I2 (lt) 2020-10-12
HUE025336T2 (en) 2016-03-29
CA2794377C (en) 2015-06-16
CN102971308A (zh) 2013-03-13
CN102971308B (zh) 2015-02-04
HN2012002039A (es) 2015-08-24
TN2012000455A1 (en) 2014-01-30
CL2012002744A1 (es) 2012-12-14
LTPA2019506I1 (lt) 2019-04-25
LT2924034T (lt) 2016-12-27
PL2552902T3 (pl) 2015-10-30
CR20120503A (es) 2013-01-09
US20110245296A1 (en) 2011-10-06
AU2011235568B2 (en) 2013-09-12
EA201290976A1 (ru) 2013-03-29
WO2011120133A1 (en) 2011-10-06
CY2019026I2 (el) 2020-05-29
HRP20150427T1 (hr) 2015-07-03
HUS1900021I1 (hu) 2019-05-28
MX2012011379A (es) 2012-11-30
ME02570B (me) 2017-06-20
AU2011235568A1 (en) 2012-11-01
BR112012024691B1 (pt) 2020-11-17
CY2019026I1 (el) 2020-05-29
CO6630126A2 (es) 2013-03-01
RS54017B1 (en) 2015-10-30
JP5281718B2 (ja) 2013-09-04
LUC00114I1 (pt) 2019-04-17
DOP2012000256A (es) 2012-12-15
LUC00113I2 (pt) 2024-05-22
NZ602670A (en) 2014-09-26
LUC00114I2 (pt) 2020-07-10
DK2924034T3 (en) 2017-02-06
HK1209121A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
BR112015007742B1 (pt) composto, composição farmacêutica, e, uso do referido composto
BR112012024691A2 (pt) composto, e, composição farmacêutica
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
TN2009000243A1 (en) Non-nucleoside reverse transcriptase inhibitors
TW200738702A (en) HIV reverse transcriptase inhibitors
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2007146230A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
BR112016022722B8 (pt) Composto, composição farmacêutica que o comprende e uso do mesmo
BRPI0920605A8 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
WO2007002458A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007002481A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007002368A3 (en) Non-nucleoside reverse transcriptase inhibitors
DOP2006000176A (es) Inhibidores de la transcriptasa reversa de vih
EA201491992A1 (ru) Новые соединения и новое применение
UA108495C2 (en) Reverse transcriptase nucleoside inhibitors
ECSP088126A (es) Inhibidores de la transcriptasa reversa de vih

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2011, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ASSOCIACAO BRASILEIRA INTERDISCIPLINAR DE AIDS; FORUM DAS ONGS AIDS DO ESTADO DE SAO PAULO - FOAESP; FORUM ONG AIDS RS; UNIVERSIDADES ALIADAS PARA O ACESSO A MEDICAMENTOS ESSENCIAIS - UAEM/BRASIL; GRUPO DE INCENTIVO A VIDA - GIV; GRUPO SOLIDARIEDADE E VIDA - 870210044574 - 17/05/2021